LONDON, Sept. 15, 2025 – AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company dedicated to rare genetic disorders, today announced encouraging results from its ongoing REACHCDM-X open-label extension study of AMO-02 in congenital and childhood-onset myotonic dystrophy type 1 (DM1). The four-year data reaffirm a favorable safety profile and support continued development of AMO-02. The company also confirmed plans to meet with the U.S. Food and Drug Administration (FDA) in Q4 2025 to discuss potential next steps toward a New Drug Application (NDA).
Science Significance
The REACHCDM-X trial represents the largest and longest interventional study ever conducted in congenital and childhood-onset DM1. Across more than 151 patient-years of exposure, AMO-02 has shown sustained tolerability and safety. Notably, participants experienced a low hospitalization rate of only 0.14 events per patient per year, and no deaths or cardiovascular events were reported. In addition, secondary endpoint analysis showed participants aged 10 years and older demonstrated little or no decline in mobility as measured by the 10-meter walk/run test over one year.
Regulatory Significance
AMO Pharma has submitted the long-term safety data to the FDA, Health Canada, and the UK MHRA. A critical FDA meeting is scheduled for Q4 2025 to evaluate the regulatory pathway for AMO-02 in congenital myotonic dystrophy, including the use of real-world evidence to potentially support NDA submission. In parallel, a Phase 3 protocol in adult-onset DM1 has been submitted to the FDA, signaling AMO Pharma’s broader ambitions to expand AMO-02’s clinical footprint.
Business Significance
Advertisement
For AMO Pharma, these findings reinforce its position as a focused innovator in rare neurogenetic disorders. By demonstrating sustained safety over four years, the company reduces risk associated with long-term therapy development. Upcoming regulatory interactions could pave the way for accelerated development, increasing AMO-02’s potential value proposition to investors, partners, and rare disease stakeholders. Regulatory clarity could also enhance opportunities for funding and collaboration in 2026.
Patients’ Significance
Patients with congenital and childhood-onset DM1 face severe, life-threatening complications with no approved therapies. The results showing low hospitalization rates and maintenance of physical function over years of therapy bring much-needed hope to families. AMO-02’s sustained safety profile highlights its potential to become the first disease-modifying treatment for DM1, addressing a significant unmet need for patients who currently lack therapeutic options.
Policy Significance
The data underline the importance of regulatory flexibility in rare diseases, particularly in leveraging real-world evidence and long-term open-label data to inform approval pathways. AMO Pharma’s work reflects broader global health policy priorities aimed at accelerating access to treatments for underserved patient populations, aligning with FDA and EMA initiatives on rare and ultra-rare disease therapeutics.
Transaction Highlights
The REACHCDM-X open-label extension study has provided four years of safety data on AMO-02 in congenital and childhood-onset myotonic dystrophy type 1, showing the drug to be generally safe and well-tolerated over more than 151 patient-years of exposure. As of August 2025, 45 participants remain on treatment, including 20 patients who have been continuously receiving AMO-02 for more than three years. Only one participant discontinued treatment due to an adverse event, while most adverse events reported were mild or moderate and consistent with the natural course of the disease. Importantly, the study recorded a hospitalization rate of just 0.14 events per patient per year, with no deaths or cardiovascular events reported. In addition, functional outcomes such as the 10-meter walk/run test showed little or no decline over one year in participants aged 10 years and older, reinforcing AMO-02’s potential clinical benefit. These results have been submitted to the FDA, Health Canada, and the UK MHRA, and AMO Pharma plans to meet with the FDA in Q4 2025 to review regulatory pathways, while also preparing a Phase 3 protocol in adult-onset DM1.
Source: AMO Pharma Limited Press Release
